Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences

Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced further expansion of its differentiated ADC pipeline through a license and commercialisation agreement with LegoChem Biosciences (LCB), a Korean biopharmaceutical company focused on the development of next-generation novel therapeutics utilising its proprietary medicinal drug discovery technologies.

Related Keywords

China ,South Korea ,Legochem Biosciences ,Dave Simpson ,Fosun Pharma ,Company Adcs ,Young ,Celltrion Inc ,Greater China ,Mirae Asset Capital ,Chief Executive Officer ,Iksuda Therapeutics ,Young Lag Cho ,Chief Development Officer ,United Kingdom Based ,Chem Biosciences ,Media Contact ,Ksuda ,Antibody Drug Conjugates ,Dcs ,Therapeutic Index ,Commercialisation Agreement ,Cb ,Orean Biopharmaceutical Company ,Edicinal Drug Discovery Technologies ,Cb14 ,Jr Dave Simpson ,R Young Lag Cho ,Yong Zu Kim ,